Healius (HLS) H1 2026 earnings summary

Executive summary

• Revenue increased 3.8% to $688.1 million in H1 FY26, with underlying EBITDA up 13.1% to $122.2 million and underlying EBIT turning positive at $7.9 million from a prior loss.

• Cost reduction initiatives, especially in labor, delivered annualized savings of $10.7 million in 1H26 and are expected to reach $15–20 million annually, with further benefits anticipated.

• Strategic focus remains on digital modernization, customer service, and expanding high-value segments such as genomics, clinical trials, and B2B services.

• Net cash position at 31 December 2025 was $11.6 million, down from $57.2 million due to non-operational outflows including ATO payments and restructuring.

• Net loss after tax widened to $30.4 million, reflecting non-recurring costs and sector pressures, while underlying loss after tax improved to $11.0 million.

Financial highlights

• Pathology revenue grew 3.5% to $666.3 million, with EBIT improving to $5.2 million from a prior loss; Agilex Biolabs revenue rose 16% to $21.8 million, with EBIT up 145.5% to $2.7 million and margin at 12.4%.

• Labor costs reduced to 49.3% of revenue in Q2, with headcount reductions and efficiency gains.

• Consumables costs fell to 15.8% of revenue, down from 16.6% prior period, despite higher volumes.

• Non-underlying items totaled $20.8 million, mainly from digital transformation and restructuring.

• Interest costs fell 29.8% to $23.6 million due to lower average debt levels.

Outlook and guidance

• FY26 earnings expected to be in line with consensus EBIT of around $48 million, with revenue and profitability weighted to H2 due to seasonality and timing of cost savings.

• High single-digit EBIT margins targeted by June 2027, driven by volume growth, pricing, technology, and cost control.

• Full benefit of cost savings to be realized from FY27 onward.

• Labour cost forecasts expected to remain broadly flat year-on-year, excluding Fair Work Commission impacts.